Minimised versus conventional cardiopulmonary bypass: outcome of high-risk patients
2009; Oxford University Press; Volume: 36; Issue: 5 Linguagem: Inglês
10.1016/j.ejcts.2009.05.045
ISSN1873-734X
AutoresAssad Haneya, Alois Philipp, Çhristof Schmid, Claudius Diez, Reinhard Kobuch, Stephan Hirt, Wolfgang Zink, Thomas Puehler,
Tópico(s)Cardiac, Anesthesia and Surgical Outcomes
ResumoCoronary artery bypass grafting (CABG) with extracorporeal circulation (ECC) is the gold standard for surgical coronary re-vascularisation. Recently, minimised extracorporeal circulation system (MECC) has been postulated a safe and advantageous alternative for multi-vessel CABG.Between January 2004 and December 2007, 244 high-risk patients (logistic EuroScore (ES)>10%) underwent CABG in our institution. ECC was used in 139 (57%) and MECC in 105 (43%) patients. Demographic data including age (MECC: 73.4+/-7.4 years; ECC: 73.3+/-6.4 years), ES (MECC: 19.2+/-9.8%; ECC: 21.4+/-11.9%), left-ventricular ejection fraction (MECC: 45.6+/-16.1%; ECC: 43.1+/-15.3%), diabetes mellitus (MECC: 14.3%; ECC: 15.1%) and COPD (MECC: 6.7%; ECC: 7.9%) did not differ between the two groups. Preoperative end-stage renal failure was an exclusion criterion. The clinical course and serological/haematological parameters in the ECC and MECC patients were compared in a retrospective manner.Although the numbers of distal anastomoses did not differ between the two groups (MECC: 3.0+/-0.9; ECC: 2.9+/-0.9), ECC time was significantly shorter in the MECC group (MECC: 96+/-33 min; ECC: 120+/-50 min, p<0.01). Creatinine kinase (CK) levels were significantly lower 6 h after surgery in the MECC group (MECC: 681+/-1505 U l(-1); ECC: 1086+/-1338 U l(-1), p<0.05) and the need of red blood cell transfusion was significantly less after MECC surgery (MECC: 3 [range: 1-6]; ECC: 5 [range: 2-9] p<0.05). Moreover, 30-day mortality was significantly lower in the MECC group as compared to the ECC group (MECC: 12.4%; ECC: 26.6, p<0.01).MECC is a safe alternative for CABG surgery. A lower 30-day mortality, lower transfusion requirements and less renal and myocardial damage encourage the use of MECC systems, especially in high-risk patients.
Referência(s)